Pancreatic ductal adenocarcinoma (PDAC), with KRAS mutation frequency of more than 85%, is characterized by one of the highest mortality rates among all malignant diseases.[32, 33] As a major oncogenic driver of PDAC, KRAS mutations are attractive targets for PDAC treatment. This evidence concerns the gene KRAS and pancreatic ductal adenocarcinoma.